Bioactive Glass as Bone Graft Substitute in Operative Treatment of Bone - a 10 Years Follow-up Study

The main aim is to evaluate the long-term safety and bone healing in the operated area and to compare bioactive glass granules with autogenous bone as a filler material.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Depressed Lateral Condyle Fracture Benign Bone Tumour Cavity Spinal Fusion

Sex eligibility

All sexes

Study type

Observational

Primary location

Turku University Hospital

Turku, FI-20521, Finland

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Written informed consent obtained; Participation of previous clinical investigation with bioactive glass

Exclusion criteria

The subject is unlikely to adhere to study procedures
Concurrent disease or condition that in the opinion of the investigator is contraindicating participation
Simultaneous participation in another medical device or investigational drug trial

Treatment and study plan

Bioactive glass and/or autogenous bone

Device

No intervention in the current study (10-year follow-up study)

Sponsors and collaborators

Lead sponsor

Vivoxid Ltd

Industry

Registry information

Official study title

Bioactive Glass (S53P4) as Bone Graft Substitute in Operative Treatment of Depressed Lateral Condyle Fractures, Benign Bone Tumour Cavities and in Spinal Fusion - a 10 Years Follow-up and Bone Density Study.

Important dates

Study start: 2008
Primary completion: 2008
Study completion: 2009
First posted: Jul 9, 2009
Registry last updated: Jul 9, 2009

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed